Tanuja Chitnis tells us about the TERIKIDS study showing a numerical reduction in clinical relapse risk and a significant reduction in time to clinical relapse with teriflunomide in paediatric patients with relapsing-remitting multiple sclerosis (5:29).
Earlier age at menarche is associated with an increased risk for type 2 diabetes and impaired glucose tolerance among women, and this association remains significant after adjustment for adiposity, suggest findings from a meta-analysis.
Adalimumab, used with or without concurrent methotrexate, appears to be well tolerated among children with polyarticular‐course juvenile idiopathic arthritis, 7-year data from the STRIVE registry show.
Continuous glucose monitoring offers many benefits to the families of young children with type 1 diabetes but also a number of challenges that cannot always be overcome, show results of a qualitative analysis conducted in the USA.
Jonathan Santoro summarises their research evaluating disability distribution in paediatric-onset multiple sclerosis using a novel scoring model, and discusses the implications for the care of patients (4:31).
Early findings point to the antitumor efficacy of the next-generation TRK inhibitor LOXO-195 in patients with NTRK fusion-positive cancers and NTRK resistance mutations acquired during treatment with first-generation agents.
Levofloxacin prophylaxis significantly reduces the risk for bacteremia among children receiving intensive chemotherapy for acute leukemia, but not among those undergoing hematopoietic stem cell transplantation, study data show.